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Background: Treatment of acute asthma is based on rapid reversal of bronchospasm and
airway inflammation. Magnesium sulphate (MgSO4) is known to have a bronchodilator
effect on smooth muscle but studies have shown conflicting results on its efficacy in acute
asthma, although its use is recommended in national and international guidelines.
Aims: To determine if intravenous MgSO4, when used as an adjunct to standard therapy,
improves the outcome in acute asthma.
Methods: A double blind, randomised placebo controlled trial comparing 1.2 g MgSO4 with
standard therapy in adult patients with acute asthma. Patients had a PEFp75% predicted
and all were treated with oxygen, nebulised salbutamol and ipratropium, and IV
hydrocortisone. They then received 1.2 g IV MgSO4 or placebo. Outcome measures were
% predicted PEF at 60min and hospital admission rates.
Results: One hundred and twenty nine patients were studied. Placebo and active
treatment groups were well matched at baseline. MgSO4 had no benefit with regards
hospital admission rates or % predicted PEF at 60min (p ¼ 0.48) for the whole group, or for
subgroups of life-threatening (p ¼ 0.85), severe (p ¼ 0.63) and moderate (p ¼ 0.67) acute
asthma.
Conclusion: This study did not show additional benefit from 1.2 g IV MgSO4 when given as
an adjunct to standard therapy for acute asthma.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Asthma is a major cause of morbidity and mortality with an
estimated 300 million sufferers worldwide, and accounts forElsevier Ltd. All rights reserved.
537 1781.
net (T.A. Bradshaw).1 in 250 deaths.1 Much of the morbidity and expense of
asthma care relates to acute exacerbations.2 Treatment of
acute asthma is based on rapid reversal of bronchospasm
and resolution of airway inflammation. The mainstay of
current treatment is inhaled b2 agonists and systemic
corticosteroids. However, up to one third of patients fail
to respond adequately to b2 agonists
3,4 and corticosteroids
require 6–8 h before effects are manifest.5 Therefore, other
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may be beneficial.
The use of magnesium sulphate in acute asthma was first
suggested in anecdotal reports over 60 years ago6,7 and it
has been shown to have a bronchodilator effect on bronchial
smooth muscle in vitro.8 Since then a number of case
reports have shown a beneficial effect of magnesium in
acute asthma.9,10 However, randomised, controlled clinical
trials have produced conflicting results on the efficacy of
intravenous magnesium sulphate in acute asthma, with
some studies showing a benefit and others not.11–14
Despite the relative paucity and conflicting nature of
studies to date, both international1 and national15 guide-
lines recommend consideration of magnesium therapy in
patients with acute severe asthma.
We have therefore carried out a study to determine if
intravenous magnesium sulphate, when used as an adjunct
to standard therapy, improves the outcome in acute asthma
exacerbations.
Methods
Study design
This was a double blind, randomised, placebo controlled
study comparing 1.2 g IV magnesium sulphate, as recom-
mended by the UK guidelines (British Thoracic Society/
Scottish Intercollegiate Guideline network [BTS/SIGN]),15 in
adult asthmatics receiving conventional treatment for acute
exacerbations.
Study population
In a teaching hospital setting all patients aged 16 and over
presenting with acute asthma were considered for enrol-
ment. Patients were eligible for entry into the study if they
had a past diagnosis of asthma in accordance with British
Thoracic Society guidelines and a PEFo75% predicted
indicating a moderate to severe attack.15 Exclusion criteria
were COPD or other chronic lung disease, pneumonia,
congestive cardiac failure, coronary artery disease, renal
insufficiency, hypertension treated with medication, preg-
nancy or inability to perform peak flow measurements.
All patients gave informed consent and the study was
approved by the Lothian Research Ethics Committee.
Patient assessment
Baseline data were obtained on presentation and included
history and examination, blood pressure, pulse, oxygen
saturations and PEF determined using a Wright hand held
meter with the best of three attempts taken. Information on
current asthma medication was also recorded.
All patients received therapy of 35% oxygen, 5mg
nebulised salbutamol, 500mcg nebulised ipratropium and
200mg IV hydrocortisone. Blood was taken for serum
magnesium levels.
After initial assessment and standard treatment, patients
were randomised to receive either 1.2 g MgSO4 in 50ml
normal saline or placebo consisting of 50ml normal saline,both intravenously over 15min. The MgSO4 and placebo
solutions were identical in appearance. Physicians and
patients were both blinded to the randomisation which
was done by random number generation under the control of
the hospital pharmacy.
Additional treatments (nebulised bronchodilators or IV
aminophylline) were given at the discretion of the attending
physician. At 60min post-infusion the decision to admit or
discharge was also made by the attending physician
Outcome measurements
The primary outcome measurement was % predicted PEF at
60min. All patients had PEF repeated at 15, 30, 45 and
60min. Hospital admission rates were the secondary out-
come and the decision to admit or discharge was made at
60min. Guidelines for hospital admission were PEF o50%
predicted, respiratory rate 425/min, pulse X110 beats/
min or inability to complete sentences in 1 breath.15 Blood
pressure and pulse were re-measured at 60min.
Statistical analysis
Data were analysed using tests for paired and unpaired
variables, w2 test and repeated measures two-way analysis
of variance as appropriate. A p value o0.05 was taken as
significant. The patients were analysed as a whole group and
also as subgroups defined depending on severity of the
attack. Those with PEF p33% predicted were considered a
‘‘life-threatening’’ attack, PEF 34–50% predicted a ‘‘severe’’
attack and 51–75% predicted a ‘‘moderate’’ attack, as
defined by the BTS/SIGN Guidelines.15
Results
One hundred and fifty patients were recruited into the study
over 2 years, with 129 included in the final analysis. The
remainder were excluded due to the subsequent recognition
of PEF 475% predicted or missing recorded data. Sixty-two
patients were randomised to receive magnesium sulphate
and 67 received placebo (Figure 1).
Patient baseline characteristics are shown in Table 1.
There was no difference in any parameter between the
magnesium and placebo groups at baseline. Final %
predicted PEF at t ¼ 60 was not significantly different
between the treatment groups (mean % predicted PEF
MgSO4 65.4 cf. placebo 62.8; mean difference, 2.6; 95%
confidence interval [CI], 4.66 to 9.93; p ¼ 0.48). There
was no difference in the change in % predicted PEF over time
between the groups (p ¼ 0.98). Hospital admission rates
were similar for both groups; MgSO4 79% (49/62), placebo
78% (52/67), p ¼ 0.98 (Table 2).
Life threatening group
Twenty-nine patients were classified as having a life-
threatening attack based on initial PEF values. Of these,
12 received MgSO4 and 17 had placebo. Baseline character-
istics were similar in both groups (Table 3). There was no
significant difference in % predicted PEF at t ¼ 60 (MgSO4
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Figure 1 CONSORT flow diagram.
Table 1 Baseline characteristics all patients (n ¼ 129).
Mg Placebo p-Value
(n ¼ 62) (n ¼ 67)
Sex M:F (%) 39:61 45:53 0.48
Age (range) 36 (18–73) 38.8 (17–73) 0.28
Inhaled steroida 76% (47/62) 63% (42/67) 0.16
Serum Mg (mmol/L) 0.82 0.81 0.7
Pulse t ¼ 0 106716.6 110717.6 0.16
Systolic BP t ¼ 0 133720.9 143727.3 0.05
% predicted PEF t ¼ 0 43.1714.5 46.5715.3 0.73
PEF t ¼ 0 (L/min) 183.3776.3 173.6771.4 0.46
aPatients receiving regular treatment prior to study entry.
Table 2 Hospital admission rates.
Magnesium Placebo p-Value
All 79% (49/62) 78% (52/67) 0.98
Life-threatening 100% (12/12) 88% (15/17) 0.5
Severe 70% (21/30) 84% (26/31) 0.32
Moderate 80% (16/20) 58% (11/19) 0.18
Table 3 Baseline characteristics life-threatening asth-
ma group (n ¼ 29).
Mg Placebo p-Value
(n ¼ 12) (n ¼ 17)
Sex M:F (%) 33:67 29:71 0.82
Age (y) 38.1716.8 34.5714.1 0.55
Inhaled steroida 67% (8/12) 59% (10/17) 0.72
Serum Mg (mmol/L) 0.79 0.76 0.56
Pulse t ¼ 0 115721.6 116715.6 0.84
Systolic BP t ¼ 0 136730.1 146725.8 0.3
% predicted PEF t ¼ 0 22.678.3 23.779.7 0.43
PEF t ¼ 0 (L/min) 93.7741.1 98.2756.3 0.49
aPatients receiving regular treatment prior to study entry.
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Figure 2 Life-threatening asthma.
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to 12.3; p ¼ 0.85) or when changes in % predicted PEF were
compared between groups over time (p ¼ 0.92) (Figure 2).
All patients were admitted in the MgSO4 group and 88%
(15/17) of the placebo group were admitted (p ¼ 0.50)
(Table 2).
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Table 5 Baseline characteristics moderate asthma
group (n ¼ 39).
Mg Placebo p-Value
(n ¼ 20) (n ¼ 19)
Sex M:F (%) 35:65 32:68 0.82
Age (y) 35.2714.3 36.2713.1 0.82
Inhaled steroida 80% (16/20) 47% (9/19) 0.07
Serum Mg (mmol/L) 0.80 0.83 0.42
Pulse t ¼ 0 101715.5 103716.5 0.75
SystolicBP t ¼ 0 131715.5 134723.7 0.94
% predicted PEF t ¼ 0 59.576.4 60.976.7 0.5
PEF t ¼ 0 (L/min) 255.5769.5 240.5733.7 0.4
aPatients receiving regular treatment prior to study entry.
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Sixty-one patients had initial PEF values between 34% and
50% predicted; 30 received MgSO4 and 31 received placebo.
Baseline characteristics are shown in Table 4. There was
no difference in % predicted PEF between groups at
endpoint (MgSO4 63.7 cf. placebo 61.6; mean difference,
2.1; 95% CI, 6.7 to 11.0; p ¼ 0.63) (Figure 3) or when
changes in % predicted PEF were compared over time
(p ¼ 0.93). Hospital admission rates were similar in both
groups (Table 2).
Moderate group
Thirty-nine patients were classified as having a moderate
exacerbation. Of these, 20 received MgSO4 and 19 received
placebo. There was no difference in baseline charac-
teristics as shown in Table 5. PEF % predicted at t ¼ 60
was 81.1 for the MgSO4 group and 82.9 for the placebo
group (mean difference, 1.8; 95% CI, 10.6 to 6.7;
p ¼ 0.67) (Figure 4). There was no difference in the
change in % predicted PEF over time between the groups
(p ¼ 0.99). Eighty percent (16/20) MgSO4 patients were
admitted compared with 58% (11/19) of the placebo group
(p ¼ 0.18).Time (mins)
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Figure 3 Severe asthma.
Table 4 Baseline characteristics severe asthma group
(n ¼ 61).
Mg Placebo p-Value
(n ¼ 30) (n ¼ 31)
Sex M:F (%) 43:57 61:39 0.15
Age (y) 34.8711.2 42.8717.1 0.03
Inhaled steroida 77% (23/30) 74% (23/31) 0.94
Serum Mg (mmol/L) 0.84 0.82 0.37
Pulse t ¼ 0 107714.5 110718.1 0.5
Systolic BP t ¼ 0 134720.4 148729.5 0.07
% predicted PEF t ¼ 0 40.374.2 41.474.6 0.31
PEF t ¼ 0 (L/min) 171.5738.9 168.3761.1 0.81
aPatients receiving regular treatment prior to study entry.
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Figure 4 Moderate asthma.Adverse events
In the MgSO4 group, there was a trend to decrease in systolic
blood pressure at t ¼ 60 (t ¼ 0, 133 cf. t ¼ 60, 123.5;
p ¼ 0.09). There was a trend towards difference in systolic
BP at t ¼ 60 between Mg and placebo groups (Mg 123.5 cf.
placebo 134.6; p ¼ 0.06). There were minor side effects
reported in 5/62 that received MgSO4, which included
headache, flushing and dizziness. Only one patient in the
placebo group (moderate exacerbation) reported an adverse
event (flushing).
Additional drugs
There was no significant difference in the use of either
additional nebulised salbutamol or intravenous aminophyl-
line between the MgSO4 and placebo groups in any severity
category (Table 6).
Discussion
This study did not demonstrate any significant benefit from
the use of 1.2 g MgSO4 in addition to standard treatment in
patients with moderate to severe asthma exacerbations.
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Table 6 Use of additional drugs.
No. of additional nebs given Total p-Value
0 1 2 3
(a) Additional nebulised salbutamol
Life-threatening Mg (n ¼ 12) 7 2 0 3 42% (5/12) 0.59
Placebo (n ¼ 17) 7 6 2 2 58% (10/17)
Severe Mg (n ¼ 30) 21 8 1 0 30% (9/30) 0.85
Placebo (n ¼ 31) 20 10 1 0 35% (11/31)
Moderate Mg (n ¼ 20) 14 6 0 0 30% (6/20) 0.9
Placebo (n ¼ 19) 12 7 0 0 37% (7/19)
(b) Additional aminophylline
Mg Placebo p-Value
17% (2/12) 24% (4/17) 1.0
13% (4/30) 3% (1/31) 0.2
5% (1/20) 0% (0/19) 1.0
Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma 147Conflicting results have been reported as to the efficacy
of MgSO4 in acute asthma.
11–14 Studies, which have reported
a positive outcome, have shown a benefit predominantly in
those classified as severe exacerbations.11,12,16 Silverman et
al. 11 administered 2 g MgSO4 or placebo to 248 patients with
an FEV1 p30% predicted on arrival. They found there was a
small but significant difference between the groups at
240min; mean FEV1 in MgSO4 group was 48.2% predicted
compared with 43.5% predicted in the placebo group.
Another study12 reported similar benefits from MgSO4 in a
subgroup of patients with FEV1 p25% predicted on arrival.
However, in the present study, subgroup analysis of the
study population found no benefit in patients with PEFp33%
predicted. Compared with Silverman et al.11 the end time
point was 60min rather than 240min. However, there were
also other significant differences in protocol. A major
difference in treatment protocol in the present study
compared with the studies reporting a positive benefit was
the use of ipratropium in addition to b2 agonists. Recent
reviews have shown that patients have a greater improve-
ment in lung function when given b2 agonists and ipratro-
pium compared with b2 agonists alone.
17,18 In a meta-
analysis of 10 studies, Rodrigo and Rodrigo19 reported a 10%
increase in pulmonary function with the addition of
ipratropium. They also found that this benefit was substan-
tially increased in patients with more severe airway
obstruction (FEV1 o35% pred). The standard use of
ipratropium in the current study may therefore have
resulted in a greater bronchodilator effect than would be
seen with b2 agonists alone, especially in the more severe
group. Any benefit of MgSO4 would then have had to be in
addition to the b2 agonist/anticholinergic effect. Also, 69%
of the patients in the present study were taking regular
inhaled corticosteroids prior to their asthma exacerbation.
The percentages of such patients in earlier studies have
been much lower (o25%). Such pre-treatment may have had
an influence on drug responses during the exacerbation.
In addition to the individual studies discussed, there has
been a systematic review.20 However, systematic reviews
can be limited by the information in the individual studiesincorporated and since all the adult studies in the review
(5 of 7) were carried out in USA Emergency Rooms in the late
1980s or early 1990s the review is unable to address factors
such as the clinical setting of the study or concomitant
therapy such as pre-existing inhaled corticosteroid, or
additional therapies such as anticholinergics.
The dose of MgSO4 in the present study was 1.2 g whereas
the majority of others demonstrating a response used
2 g.11,12 Both Okayama et al.21 and Noppen et al.22 have
reported an improvement in lung function in response to
MgSO4 in a dose dependent manner suggesting optimal
bronchodilation may be achieved using higher doses of
MgSO4. The lack of response in this study may have been
influenced by the choice of dosing at the lower end of the
recommended range.
Classification of the severity of the attack may be an
important determinant of response to MgSO4 and hence
further explain the discrepancy in results between the
present study and others showing a positive benefit. Silver-
man et al.11 hypothesised that attack severity may influence
the response to MgSO4 and when data were reanalysed it was
found that the effect of MgSO4 on pulmonary function was
greatest in those with FEV1 p25% with no apparent benefit
obtained in patients whose initial FEV1 was closer to 30%
predicted. The study by Skobeloff et al.16 included patients
who had failed to respond to initial treatment with b2
agonists and reported a beneficial effect with MgSO4 in this
severe group.
Despite this evidence being restricted to ‘‘life-threaten-
ing’’ exacerbations (% predicted PEF o25%), guidelines are
recommending the use of magnesium in ‘‘severe’’ exacer-
bations (% predicted PEF o60% after 1 h of care [flowchart
GINA], % predicted PEF o50% [BTS/SIGN]). (We emphasise
the point of the flowchart in the GINA guidelines, since the
text actually quotes PEF 25–30% predicted for adults.
Nevertheless emergency rooms are more likely to employ
use of the flowcharts of guidelines rather than full text). In
the current study, 90 of 129 patients were classed as
‘‘severe’’ by BTS/SIGN standards but there was still no
significant benefit shown with magnesium. However, we
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group may have been too small to detect a significant
difference. Nevertheless, other studies of patients with %
predicted PEF o25% predicted have also failed to demon-
strate a response, suggesting that other factors or clinical
parameters may contribute to the efficacy of MgSO4 in acute
asthma.14,23
The exact mechanism of the effect of MgSO4 in acute
asthma remains unclear but it may have a direct pharma-
cological effect or act by correcting pre-existing hypomag-
nesaemia.
Magnesium is involved in calcium transport across the cell
membrane, which determines intracellular calcium content.
Thus, by acting as a calcium channel blocker, magnesium
may cause relaxation of bronchial smooth muscle.24 Magne-
sium also causes inhibition of cholinergic neuromuscular
transmission, decreases the depolarising action of acetyl-
choline at the neuromuscular end-plate and depresses
excitability of smooth muscle membranes.25 Magnesium
deficiency may then lead to an increased excitation of
bronchial smooth muscle cells and consequent bronchocon-
striction.26
Serum magnesium levels in the present study were all
within the normal range. However, magnesium is predomi-
nantly an intracellular ion and serum levels may not reflect
intracellular content. It is therefore possible to have an
intracellular hypomagnesaemia in the presence of a normal
serum magnesium.27 Studies have demonstrated that in-
tracellular magnesium content is significantly lower in
patients with asthma compared with non-asthmatic popula-
tions28,29 although others have disputed this.30 Importantly,
it is recognised that some treatments used in acute
exacerbations can affect magnesium levels. In particular,
the use of b2 agonists can decrease magnesium levels by
increasing urinary loss or by causing intracellular shift.31
This may be relevant in explaining the conflicting results
regarding the benefits or lack of effect of MgSO4. In two
studies showing a positive effect, a total of 5 2.5mg
nebulised salbutamol was given to all patients.11,12 In the
present study, all patients received 1 dose of 5mg nebulised
salbutamol and only 32% of the MgSO4 group and 41% of the
placebo group (p ¼ 0.35) received further doses of b2
agonists. Similarly, in a study by Tiffany et al.23 who found
no benefit with MgSO4 in severe exacerbations, a total dose
of 7.5mg of salbutamol was used. Evidence suggests that
7.5mg nebulised salbutamol is as effective as 22.5mg in
providing optimal treatment in acute asthma.32 Therefore,
high doses of b2 agonists may not provide additional
bronchodilator benefit and may reduce magnesium levels
although the influence of this on biological availability is
unclear. Similarly, aminophylline has also been shown to
decrease magnesium levels by increasing renal excretion.33
In addition to the bronchodilating properties of magne-
sium, it has also been suggested that magnesium may exert
an anti-inflammatory effect in asthma. Cairns et al.34 have
shown that in clinically relevant concentrations, magnesium
attenuates the neutrophil respiratory burst causing a
decrease in superoxide production. All patients in the
present study, as well as in others, received anti-inflamma-
tory treatment with intravenous steroids at presentation.
These take 6–8 h to have effect and are unlikely to be
responsible for any earlier improvement in lung function.However, in this study, the majority of patients were
receiving inhaled steroids prior to the exacerbation (76% in
MgSO4 group and 63% in placebo group; no significant
difference). This is a considerably higher percentage than
several of the studies showing a beneficial effect with
MgSO4,
11,12,16 with less than 30% patients in each study
receiving prior treatment with inhaled corticosteroids. If
some of the benefit seen with MgSO4 in acute asthma is
attributable to an anti-inflammatory effect, it is possible
that this may be more pronounced in those patients who
were not already receiving inhaled steroids prior to the
exacerbation.
Hospital admission rates in this study were not signifi-
cantly different between the MgSO4 and placebo groups at
any severity level. However, hospital admission is dependent
on numerous other factors such as age, home environment,
compliance with treatment, time of arrival in hospital and
prior management in primary care. It is therefore a weak
surrogate for response to treatment.
In conclusion, this study shows that 1.2 g IV magnesium
sulphate is not effective after 1 h in a range of patients with
acute asthma and an initial PEF o75% predicted. It also
failed to show benefit in the 90 patients defined as severe by
BTS/SIGN criteria (PEFo50% predicted). Other studies have
reported limited benefits of magnesium confined to patients
with FEV1 o25% predicted. These studies, however, have
not evaluated the benefit of magnesium in the context of
treatment including ipratropium bromide or when most
patients are already taking inhaled corticosteroids. We
would recommend, therefore, that national guidelines for
asthma management (BTS/SIGN) should be modified to
provide a more cautious statement of benefit of magnesium
sulphate in acute, severe asthma and that international
guidelines (GINA) should be less ambiguous between
recommendations in the text compared with the diagrams,
and should consider whether the limited benefits of
magnesium in the severest patients may be eroded by use
of nebulised ipratropium bromide.References
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